All In Biotech

Drug Trial Radar · NCT05163223

Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients With Breast Cancer

A Phase 2 Study to Evaluate the Efficacy and Safety of an Adjuvant Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients With HER2 Low Breast Cancer (Cornerstone-001)

Last checked: Nov 19, 2026Latest source record: Jun 17, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

10

Actual

Start

Feb 28, 2022

Primary completion

May 31, 2024

Study completion May 31, 2024

Sponsor

Lead sponsor
Aston Sci. Inc.Industry
Sponsor type
Industry
First posted
Dec 20, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of an adjuvant treatment of therapeutic cancer vaccine (AST-301, pNGVL3-hICD) in patients with HER2-low expression (IHC 1+ or 2+ and ISH-) and hormone receptor-negative(ER-, PR-) breast cancer with residual disease after neoadjuvant treatment. Patients will be randomized 1:1 to either the Experimental arm (combination of AST-301/rhuGM CSF and standard adjuvant therapy) or the Control arm (combination of placebo/rhuGM CSF and standard adjuvant therapy). Standard adjuvant chemotherapy will be pembrolizumab or capecitabine. Adjuvant therapy will be administered in compliance with the NCCN guideline for breast cancer (Version 8, 2021), and IP (AST-301) will be administered 3 times every 3 weeks in the adjuvant treatment period, with a booster administered at 24 weeks (±7 days) post the third dose of IP administration. Survival follow up will be performed to determine invasive Disease Free survival(iDFS).

Conditions

  • Breast Cancer

Interventions

  • AST-301(pNGVL3-hICD)Biological

    Q3W, 3 cycles, Plus a booster at 24 weeks post the third vaccination, Intradermal injection

  • rhuGM-CSFDrug

    Q3W, 3 cycles, Plus a booster at 24weeks post the third vaccination, Intradermal injection

  • PlaceboDrug

    Q3W, 3 cycles, Plus a booster at 24 weeks post the third vaccination, Intradermal injection

  • PembrolizumabDrug

    Q3W; IV infusion

  • CapecitabineDrug

    On days 1-14 (Q3W), BID ; Oral administration,

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 2-year invasive disease free survival rate (iDFS)Time frame: Overall study period approximately up to 4years (End of study in this study is defined as 2years frm the date of last Patient In.

Locations

17 sites in 2 countries. Site status is shown where the registry gives one.

  • Ironwood Cancer and Research Centers

    Chandler, Arizona

  • Scripps Health

    La Jolla, California

  • Moffitt Cancer Center

    Tampa, Florida

  • University of Illinois Cancer Center

    Chicago, Illinois

  • Nebraska Cancer Specialist

    Omaha, Nebraska

  • Gabrail Cancer Center Research

    Canton, Ohio

  • The Ohio State University Comprehensive Cancer Center

    Columbus, Ohio

  • Toledo Clinic Cancer Center

    Toledo, Ohio

  • Providence Cancer Institute

    Portland, Oregon

  • University of Washington

    Seattle, Washington

  • Changhua Christian Hospital

    Changhua, Taiwan

  • Kaohsiung Medical University Chung-Ho Memorial Hospital

    Kaohsiung City, Taiwan

  • China Medical University Hospital

    Taichung, Taiwan

  • Chi Mei Medical Center

    Tainan, Taiwan

  • Koo Foundation Sun Yat-Sen Cancer Center

    Taipei, Taiwan

  • National Taiwan University Hospital

    Taipei, Taiwan

  • Taipei Veterans General Hospital

    Taipei, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.